Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

BACKGROUND: Antibodies inhibiting the programmed death receptor 1 (PD-1) have shown significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD-1 blockade in patients with uveal melanoma has not been well characterized. METHODS: 58 stage IV uveal melanoma pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Algazi, Alain P., Tsai, Katy K., Shoushtari, Alexander N., Munhoz, Rodrigo R., Eroglu, Zeynep, Piulats, Josep M, Ott, Patrick A., Johnson, Douglas B., Hwang, Jimmy, Daud, Adil I., Sosman, Jeffrey, Carvajal, Richard D., Chmielowski, Bartosz, Postow, Michael A., Weber, Jeffrey S., Sullivan, Ryan J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5767160/
https://ncbi.nlm.nih.gov/pubmed/27533448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30258
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados